✦ LIBER ✦

Dose optimization of recombinant factor VIIa for control of mild to moderate bleeds in inhibitor patients: improved efficacy with higher dosing

✍ Scribed by Thomas C Abshire

Book ID: 117821761
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 139 KB
Volume: 41
Category: Article
ISSN: 1532-8686
DOI: 10.1053/j.seminhematol.2003.11.002

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Experience with a single dose of recombi

Experience with a single dose of recombinant activated factor VII for the management of mild-to-moderate bleeds in haemophilia

✍ D. ALMAGRO; O. AGRAMONTE; D. CASTILLO; Y. ZAMORA; J. M. BALLESTER 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 55 KB

Recombinant factor VIIa: review of effic

Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors

✍ T. Abshire; G. Kenet 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 168 KB

Patient- and caregiver-reported bleeding

Patient- and caregiver-reported bleeding symptoms and reasons for starting and stopping treatment with recombinant factor VIIa: analysis of the Dosing Observational Study in Haemophilia (DOSE)

✍ L. A. VALENTINO; C. E. WALSH; M. T. REDING; G. A. YOUNG; O. LEVENDOGLU-TUGAL; D. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB

Recombinant factor VIIa analog (vatrepta

Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial

✍ ERICH V. DE PAULA; KAAN KAVAKLI; JOHNNY MAHLANGU; YASMIN AYOB; STEVEN R. LENTZ; 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 231 KB

A multicentre, randomized, double-blind,

A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study

✍ Bruno Dubois; Ian McKeith; Jean-Marc Orgogozo; Owen Collins; Didier Meulien 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 3 views

Background. Metrifonate is a long-lasting acetylcholinesterase inhibitor being developed for the symptomatic treatment of Alzheimer's disease (AD). Objectives. This study compared the ecacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate AD, over a 26-week tre

Single-dose (270 μg kg−1) recombinant ac

Single-dose (270 μg kg−1) recombinant activated factor VII for the treatment and prevention of bleeds in haemophilia A patients with inhibitors: experience from seven European haemophilia centres

✍ B. PAN-PETESCH; P. LAGUNA; A. MITAL; J. STANLEY; M. F. TORCHET; S. Z. SALEK; P. 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB